Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

François Mach, Colin Baigent, Alberico L. Catapano et al. · European Heart Journal · 2019 · 8.9K citations · Full text

Medicine, Cardiology, Internal Medicine +17

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano et al. · New England Journal of Medicine · 2015 · 4.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet · 2004 · 3.8K citations

Medicine, Pharmacotherapy, Preventive Medicine +9

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek et al. · New England Journal of Medicine · 2018 · 3.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Deepak L. Bhatt, Philippe Gabríel Steg, Michael Miller et al. · New England Journal of Medicine · 2018 · 3.2K citations

Medicine, Cardiology, Pharmacology +14